Objective Previous studies have reported distinct serological profiles of lipid, urate and ferritin in Western patients with amyotrophic lateral sclerosis (ALS). We aimed to examine the levels of these serological factors and their relationship to disease progression in Japanese ALS patients. Methods Ninety-two patients with definite or probable ALS who fulfilled the revised El Escorial criteria were analyzed for clinical and serological variables. Serological data at the time diagnosed with ALS were compared to those of 92 age/sex/body mass index-matched healthy controls. Results Compared to controls, urate and creatinine (Cr) levels were decreased and ferritin levels were increased significantly in sera of male and female patients with ALS. Significant increases of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride levels were found in female ALS patients. The annual decline of ALS Functional Rating Scale-Revised (ALS-FRS) and forced vital capacity (FVC) were inversely correlated with serum TC, LDL-C, Cr and urate levels, and were positively correlated with serum ferritin levels. Multivariate analysis showed that the rapid worsening of annual ALS-FRS and FVC was associated with serum levels of TC, LDL-C, Cr, urate and ferritin. Conclusion The present study indicated that serum levels of TC, LDL-C, Cr, urate and ferritin were correlated with clinical deterioration in ALS patients. These results are similar to those in Western patients. Metabolic and nutritional conditions of lipid, urate and iron could contribute to disease progression in ALS patients. Further studies investigating high nutrition diets and iron chelation for the treatment of ALS are warranted.
Introduction
Several candidate biomarkers for disease progression, survival and therapeutic monitoring, have been proposed for amyotrophic lateral sclerosis (ALS) (1, 2) . Plasma and serum provide the most useful and convenient samples to test for such biomarkers of ALS. Previous serological studies suggested distinct profiles of lipid, urate and ferritin levels in sera of European, Israeli and North American patients with ALS (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Recent studies have reported that dys- 
Materials and Methods

ALS patients and controls
ALS was diagnosed according to the revised El Escorial criteria (15) . As no patients had a family history of ALS and mutations in the gene encoding superoxide dismutase 1 (SOD1), the diagnosis was apparently sporadic ALS without SOD1 mutations. A total of 92 patients diagnosed serially with definite or probable ALS were enrolled in the present study. ALS patients who had hypertension, renal dysfunction, gout attacks, chronic inflammatory diseases, a percutaneous enterogastrostomy, iron, urate-or lipid-lowering medication were excluded from this study. Ninety-two healthy volunteers (controls) were matched for age, sex and BMI. The mean age (SD) was 58.8 (12.7) years in ALS patients and 59.2 (11.6) in control subjects. The mean symptom duration (SD) was 23.7 (21.3) months. Sixty-nine patients were diagnosed with definite ALS and 23 with probable ALS on the diagnostic criteria (15) . Ten patients experienced bulbar onset and 82 patients experienced limb onset. All patients were treated with riluzole. The mean BMI (SD) at the time of diagnosis was 22.6 (2.7) kg/m 2 in ALS patients and 22.8 (3.5) in control subjects (Table 1) . The informed consent was obtained from all patients and control subjects. The present study was approved by the Ethical Committee of Toho University Omori Medical Center.
Clinical and serological variables
Clinical variables of ALS patients were analyzed for age, sex, onset site, symptom duration, the ALS Functional Rating Scale-Revised (ALS-FRS) (16), BMI and forced vital capacity (FVC). The levels of 11 serological factors were compared statistically between ALS patients and control subjects: total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), fasting blood sugar (FBS), creatinine (Cr), blood urea nitrogen (BUN), urate, iron, transferrin and ferritin. The annual decline of ALS-FRS or FVC was calculated as the value at the first examination the value at the post-one year examination/100%. Monthly decline of ALS-FRS was calculated as the annual decline of ALS-FRS/12.
ALS-FRS decline !1.0 point/month and the annual decline of FVC !30% were defined as rapid worsening of ALS-FRS and FVC.
Measurement of serological factors
Fasting blood samples were obtained from the antecubital vein and centrifuged within 1 hour. Baseline serological data were obtained from serum samples at the first time of ALS diagnosis. Serum levels of urate, TC, TG and HDL-C were measured using Olympus AU600 chemistry analyzer (Olympus Corp., Tokyo, Japan). LDL-C was calculated with the Friedewald formula as follows: LDL-C (mg/dL) = TC (mg/ dL) -HDL-C (mg/dL) -0.2 × TG (mg/dL) (17) . Serum iron levels were measured using 2-nitroso-5-[N-n-propyl-N-(3-sulfopropyl) amino] phenol with a JCA-BM2250 (Japan Electron Optics Laboratory, Mitaka, Japan). Serum transferritin levels were measured using an immunoturbidimetric assay. Serum ferritin levels were analyzed using an electrochemiluminescent immunoassay with a cobas 6000 (Roche Diagnostics, Tokyo, Japan). Serum Cr levels were determined using an enzymatic method. Serum levels of FBS and BUN were measured using the established methods.
Data analysis
Comparison of serological factors between the ALS group and the control group was performed using unpaired Student's t-test. Binary correlation between baseline levels of serological factors, symptom duration and the annual decline of ALS-FRS or FVC was analyzed by Spearman's rho correlation. Multiple logistic regression analysis was performed to identify independent risk factors for ALS-FRS decline !1 point /month and the annual decline of FVC !30% in male and female patients. All significance levels were set at 0.05. Data were expressed by mean (SD).
Results
Univariate analysis of serological factors between ALS patients and controls
Serological data are shown in Table 2 . Compared to controls, serum urate and Cr levels were significantly decreased in male and female patients with ALS. Serum ferritin levels were increased significantly in male and female patients with ALS. Serum levels of TC, LDL-C and TG were significantly increased in female, but not male patients with ALS. Serum FBS, BUN, iron and transferrin levels did not differ statistically between ALS patients and control subjects.
Binary correlation between baseline levels of serological factors, symptom duration and the annual decline of ALS-FRS or FVC
ALS-FRS and FVC were 40.3 (3.9) points and 94.3 (19.0) % at baseline, respectively ( Table 1 ). The annual decline of ALS-FRS and FVC were inversely correlated with baseline serum levels of TC, LDL-C, Cr and UA ( Fig. 1-4) , and positively correlated with baseline serum ferritin levels (Fig. 5) . ALS-FRS and FVC were not linked to baseline serum levels of TG, HDL-C, FBS, BUN, iron and transferrin. There were no significant correlations between baseline levels of serological factors and symptom duration.
Multiple logistic regression analysis for rapid worsening of ALS-FRS and FVC
Rapid worsening of ALS-FRS and FVC were not associated with age or onset site in male (Table 3 , 4) and female patients (Table 5, 6) . A significant association was found between ALS-FRS decline !1/month and baseline levels of BMI, TC, LDL-C, urate, Cr and ferritin in both men (Table 3) and women (Table 5 ). Baseline serum levels of HDL-C, TG, FBS, BUN, iron and transferrin were not significantly correlated with ALS-FRS decline !1/month (Table 3, 5). The annual decline of FVC !30% was significantly linked to baseline serum levels of TC, LDL-C, urate, Cr and ferritin in men (Table 4) and women (Table 6 ). Baseline levels of BMI, HDL-C, TG, FBS, BUN, iron and transferrin were not correlated with rapid worsening of FVC (Table 4, 6 ).
Discussion
The present study revealed that the annual decline of ALS-FRS and FVC were associated with serum levels of TC, LDL-C, urate, Cr and ferritin at the time of diagnosis with ALS. The baseline serum levels of TC, LDL-C, Cr, urate and ferritin were independent factors of rapid worsening of ALS-FRS and FVC. The main studies which previously investigated lipid, urate and ferritin levels in blood samples of ALS patients are summarized in Table 7 , and are compared with the present study in the below discussion.
Serum lipid levels in ALS patients
Four large European studies previously showed that serum lipid levels were related to better respiratory function or longer survival in ALS patients (3) (4) (5) (6) . A French study by Dupuis and colleagues (3) reported that serum levels of TC and LDL-C were significantly increased in ALS patients, and the elevation of LDL-C/HDL-C ratio was associated with prolonged survival. An Italian study by Chiò et al. (4) demonstrated univariate correlation between respiratory dysfunction and decreased serum lipid levels in ALS patients. Significant decreases of TC, HDL-C, TG levels and LDL-C/ HDL-C ratio were found in ALS patients with FVC <70%. A German study by Dorst and colleagues (5) has revealed that BMI and serum levels of TC and TG were significant factors for survival in ALS patients. Age at onset and BMI were independent predictors of survival. In a Dutch serological study by Sutedja et al. (6) , TC and LDL-C levels were decreased, and HDL-C levels were increased in both male and female patients. The mean TC and LDL-C levels were lower in patients with FVC <70%. Higher serum LDL-C/HDL-C ratio was correlated with increased survival. A North American study by Paganoni and colleagues (14) analyzed multivariate correlation between serum lipid levels, BMI, ALS-FRS, FVC and survival in ALS patients. Only BMI was found to be an independent survival factor. A Ushaped association was found between BMI and mortality and the highest survival was associated with the BMI level of 30-35 kg/m 2 . At first, the present study pointed out higher serum levels of TC, LDL-C and TG in Japanese women with ALS. Previous European studies showed disparate results of serum lipid levels between ethnic groups (3-6). Compared to controls, gender difference of serum lipid levels remains unknown in the present study. Ethical and environmental backgrounds may lead to different lipid levels in sera of male and female patients with ALS. Moreover, the present study revealed that baseline serum TC and LDL-C levels were independent predictors for rapid worsening of ALS-FRS and FVC in male and female patients. Baseline BMI was linked to rapid decline of ALS-FRS. Finally, the present and previous studies highlight a major impact of nutrition on survival of ALS patients (3) (4) (5) (6) 14) . Both lipid metabolism and nutritional status could be closely related to prognosis for ALS patients.
Serum urate levels in ALS patients
Urate is produced from purines by the enzyme xanthine oxidase. This substance is a natural antioxidant (18, 19) and can scavenge superoxide and nitrogen radicals (20) (21) (22) (23) . Oxidative stress plays a crucial role in the pathogenesis of ALS (24) (25) (26) (27) (28) . Glutamate neurotoxicity is also considered as a possible causative mechanism in ALS (28) . Urate was reported to protect spinal cord neurons against glutamate neurotoxicity in rat embryo culture (29) . With respect to serum urate levels in ALS patients, an Israeli study described lower urate levels in sera of ALS patients compared to controls matched for age, sex and BMI (7) . The univariate analysis showed that relative reduction of serum urate levels was inversely correlated with ALS-FRS decline rate. Our previous study also suggested lower serum urate levels in ALS pa- tients compared to age/sex/BMI-matched controls (8) . Another Japanese study described no significant changes of plasma urate levels between ALS patients and controls. However, slowly progressive patients had relatively higher urate levels than those of rapidly progressive patients (30) . A recent Italian study described decreased levels of urate in sera of ALS patients (9) . ALS patients with long disease duration had significantly lower serum urate levels compared to controls. Greater reductions of serum urate levels were observed in patients with bulbar onset compared to patients with limb onset (9) . Malnutrition might induce lower serum urate levels. The present study indicated that baseline serum urate levels were an independent factor for rapid worsening of ALS-FRS or FVC. Thus, higher urate levels could have favorable effects on both nutrition and disease progression in ALS patients.
Iron metabolism and serum ferritin levels in ALS patients
Iron is known to act as an important cofactor for many enzymes involved in DNA, RNA or protein synthesis, mitochondrial oxidation reactions and other metabolic processes.
However, labile iron could cause damage to DNA, lipids and proteins through oxidative stress (31) . Oxidative damage contributes to the pathogenesis in patients with sporadic and familial ALS (24) (25) (26) (27) (28) . Impairment of iron homeostasis may trigger motor neuron degeneration in ALS patients. Elevated levels of iron have been found in the spinal cord and brain of ALS patients (32) (33) (34) (35) . Expression of several iron regulators is changed in ALS patients (36) . Transferrin has been shown to localize in the Bunina body, which is the fundamental pathological feature in ALS patients (37) . Recent genetic linkage studies have reported that a polymorphism in the iron metabolism gene HFE, which is related to hemochromatosis, an iron overload disorder, is a genetic risk factor for ALS (38) (39) (40) (41) . Ferritin is the major storage protein for iron and manages cellular iron (42) . Serum ferritin levels are used as a marker for iron storage in humans (43) . The nonspecific acute phase response can also influence serum ferritin levels (44) . Previous North American and England studies showed higher ferritin levels in sera of male and female ALS patients (10, 11) . There were no differences of acute phase response between ALS patients and control subjects in the study by Goodall and colleagues (11) . Therefore, Goodall et al. (11) speculated that higher serum ferritin levels could be implicated in increased storage of iron and alternation of iron-containing myoglobin due to the ongoing muscle degradation in ALS patients. In another related study (12) , increased serum ferritin levels over one year were correlated with rapid progression of muscle weakness and shorter survival. A previous study by Mitchell et al. (13) revealed higher L-ferritin levels and lower transferrin levels in plasma of ALS patients. The present study also suggested higher serum ferritin levels in ALS patients, and a significant association between serum ferritin levels and rapid worsening of ALS-FRS and FVC. The disruption of iron homeostasis and ongoing inflammatory processes might cause serological changes of ferritin, leading to motor neuron degeneration in ALS patients.
Conclusion
The present study indicated that baseline serum levels of TC, LDL-C, Cr, urate and ferritin were associated with clinical progression in ALS patients. These clinicoserological relationships in Japanese ALS patients are similar to those previously found in European, Israeli and North American ALS patients (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The metabolism and nutrition of lipid, urate and iron could play a crucial role in the progression of ALS. Generally, environmental factors of diet and exercise influence the levels of these serological factors. Moreover, serum levels of urate, ferritin and lipid have been associated with the progression of other neurodegenerative diseases, including Parkinson's disease (45) (46) (47) and Alzheimer's disease (48) (49) (50) (51) . Thus, nutritional management might be an important and common therapy for slowing progression in patients with neurodegenerative disorders. Further studies are needed to elucidate whether high nutri- 
